Icotrokinra, an IL-23 Receptor Targeted Oral Peptide, in Biologic-Naïve Participants With Active Psoriatic Arthritis: Results Through Week 24 of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Kishimoto M, Nash P, Mease P, et al. (2026). ACR Convergence 2026 (late-breaking abstract).
Summary
A late-breaking conference abstract from ACR Convergence 2026. It reports ICONIC-PsA 1, a randomised, double-blind, placebo-controlled phase 3 trial of once-daily oral icotrokinra, a peptide that blocks the IL-23 receptor, in 552 biologic-naive adults with active psoriatic arthritis. At week 16, 58% of participants on 200 mg had at least a 20% improvement in joint symptoms (ACR20), compared with 41% on placebo. Among participants with psoriasis at baseline, 57% on icotrokinra and 14% on placebo had clear or almost clear skin. The 400 mg dose added no benefit over 200 mg. Adverse-event rates were similar to placebo, and responses were sustained or increased through week 24. The trial is from Johnson & Johnson. The abstract page lists 20 October 2026 as the first publication date, and the poster session is 10 November 2026. This is a conference abstract, not yet a peer-reviewed paper.